Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Assets (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Other Non-Current Assets for 12 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed 0.0% to $17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $17000.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Assets hit $17000.0 in Q4 2025 for Guided Therapeutics, roughly flat from $17000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $18000.0 in Q1 2021 to a low of $17000.0 in Q2 2021.
  • Historically, Other Non-Current Assets has averaged $17050.0 across 5 years, with a median of $17000.0 in 2021.
  • Biggest YoY gain for Other Non-Current Assets was 5.88% in 2021; the steepest drop was 96.55% in 2021.
  • Year by year, Other Non-Current Assets stood at $17000.0 in 2021, then changed by 0.0% to $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then changed by 0.0% to $17000.0 in 2024, then changed by 0.0% to $17000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for GTHP at $17000.0 in Q4 2025, $17000.0 in Q3 2025, and $17000.0 in Q2 2025.